Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.09 |
|---|---|
| High | 0.097 |
| Low | 0.088 |
| Bid | 0.0943 |
| Offer | 0.0945 |
| Previous close | 0.0988 |
| Average volume | 45.86m |
|---|---|
| Shares outstanding | 55.68m |
| Free float | 50.49m |
| P/E (TTM) | -- |
| Market cap | 5.50m USD |
| EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
- Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
- Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
- Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
- Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
More ▼
